Christopher Wedell, MD
Family Medicine · Saint Louis, MONPI 1356780936
Payments from drug & device makers
Across 378 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$918
- Pfizer$768
- Novo Nordisk$669
- Lilly USA, LLC$520
- AstraZeneca$450
- Amgen$415
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,210100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $918 |
| Pfizer | 57 | $768 |
| Novo Nordisk | 48 | $669 |
| Lilly USA, LLC | 29 | $520 |
| AstraZeneca | 27 | $450 |
| Amgen | 27 | $415 |
| GSK | 20 | $309 |
| Johnson & Johnson | 15 | $252 |
| E.r. Squibb & Sons, L.L.C. | 13 | $211 |
| Boehringer Ingelheim | 12 | $204 |
| Sanofi-aventis U.S. LLC | 11 | $191 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $189 |
| Amarin Pharma, Inc. | 8 | $123 |
| Merck | 9 | $123 |
| Otsuka America Pharmaceutical, Inc. | 6 | $120 |
| Astellas Pharma US Inc | 6 | $94 |
| Bayer | 6 | $94 |
| Abbott | 4 | $71 |
| Phathom Pharmaceuticals, Inc. | 2 | $59 |
| Novartis | 4 | $57 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Xeris Pharmaceuticals, Inc. | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Endo Pharmaceuticals Inc. | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$6,210 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 171 | $164,453 |
| OzempicSemaglutide | 113 | $107,853 |
| JardianceEmpagliflozin | 65 | $76,176 |
| FarxigaDapagliflozin Propanediol | 55 | $47,218 |
| XareltoRivaroxaban | 35 | $40,949 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $39,698 |
| RybelsusSemaglutide | 14 | $35,147 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $33,558 |
| MounjaroTirzepatide | 23 | $32,324 |
| ProliaDenosumab | 12 | $19,704 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $19,499 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $15,255 |
| TrulicityDulaglutide | 14 | $15,051 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 44 | $12,594 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $768 | $169,083186 claims |
| Novo NordiskOzempic, Rybelsus | $669 | $143,000127 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta | $309 | $78,170121 claims |
| Boehringer IngelheimJardiance | $204 | $76,17665 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $450 | $62,47369 claims |
| Lilly USA, LLCMounjaro, Trulicity | $520 | $47,37537 claims |
| Johnson & JohnsonXarelto | $252 | $40,94935 claims |
| AmgenProlia | $415 | $19,70412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Saint Louis
- Rupal TrivediSaint Louis$10.6M
- Emily DoucetteSaint Louis$155K
- Michael DonovanSaint Louis$78K
- Jarad SchwartzSaint Louis$36K
- Christina RobinsSaint Louis$27K
- Michael SpeziaSaint Louis$26K
- Amanda BooneSaint Louis$17K
- David GlickSaint Louis$17K
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.